Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | $0.00 | $0.00 | $1.23M |
| Operating income | — | -$1.01M | -$713K | -$51.4M | -$116M | -$44.3M | -$27.8M | -$18.5M | -$16.2M |
| Operating margin | — | — | — | — | — | — | — | — | -1324.4% |
| Net income | — | $66.1K | $408K | -$51.8M | -$93.1M | -$39.8M | -$30.1M | -$25.1M | -$28.6M |
| Net margin | — | — | — | — | — | — | — | — | -2336.5% |
| EPS (diluted) | — | -$0.29 | -$0.11 | -$1.51 | -$1.98 | -$0.60 | — | — | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | — | -$473K | -$793K | -$2.27M | -$37.7M | -$39.8M | -$21.7M | -$10.6M | -$14.1M |
| Capital expenditures | — | — | — | $2.00K | $7.00K | $10.0K | $3.00K | $0.00 | — |
| Free cash flow | — | — | — | -$2.27M | -$37.7M | -$39.8M | -$21.7M | -$10.6M | — |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | — | — | $877K | $1.86M | $27.6M | $20.1M | $4.59M | $1.44M | $7.80M |
| Total assets | $69.6M | $70.8M | $32.1M | $2.94M | $32.7M | $25.8M | $7.32M | $3.65M | $13.0M |
| Total liabilities | $93.2K | $1.26M | $2.57M | $46.7M | $11.9M | $18.4M | $19.0M | $26.9M | $28.9M |
| Long-term debt | — | — | — | — | — | $10.5M | $9.16M | — | — |
| Shareholders' equity | $5.00M | $5.00M | -$4.84M | -$43.8M | $20.8M | $7.41M | -$11.7M | -$23.2M | -$15.9M |
| Retained earnings | -$105K | -$38.9K | $369K | -$90.2M | -$183M | -$223M | -$253M | -$278M | -$307M |
| Shares (wtd avg diluted) | 2.59M | 2.73M | 2.84M | 34.3M | 46.9M | 65.8M | 7.58M | 10.6M | 21.4M |
Every figure is extracted from NRX Pharmaceuticals, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.